The role of PLA2R testing in pre- and post-renal transplant monitoring in membranous nephropathy

Autoimmune Content | Nephrology

The role of Anti-PLA2R and other biomarkers in the diagnosis of membranous nephropathy

Presented on: 2/17/2022

Abstract

Primary membranous nephropathy (MN) is a kidney-specific autoimmune disease that is a major cause of nephrotic syndrome. The autoimmune nature of pMN was first discovered upon the identification of antibodies to the phospholipase A2 receptor (PLA2R). Antibodies to PLA2R occur in 70% to 80% of patients with pMN and have been shown to have a high diagnostic value. Recent guidelines for the management of glomerular diseases have highlighted the importance of anti-PLA2R antibody detection for pMN diagnosis, monitoring, and transplant evaluation. In this webinar, Dr. Laurence Beck introduces the pathogenesis of pMN, and highlights the role of anti-PLA2R and other biomarkers in pMN diagnosis and monitoring.